July 18, 2025
Daiichi Sankyo and AstraZeneca’s Enhertu gains breakthrough therapy status
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation (BTD) to Enhertu, a targeted HER2-directed antibody-drug conjugate (ADC), discovered by Daiichi Sankyo and collaboratively developed and marketed along with AstraZeneca.